Drug
Difelikefalin
Difelikefalin: highest development phase Phase 3, developed by Cara Therapeutics, Fresenius Kabi, Vifor Pharma. 8 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Cara Therapeutics, Fresenius Kabi, Vifor Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| Difelikefalin 1 mg Oral Tablet NCT05342623 | Phase 3 | Chronic Kidney Diseases |
| Difelikefalin Injection NCT05885737 | Phase 3 | Uremic Pruritus |
| difelikefalin 0.25 mg NCT05387707 | Phase 3 | Pruritus |
| Difelikefalin 1 mg Oral Tablet NCT05356403 | Phase 3 | Chronic Kidney Diseases |
| difelikefalin 2.0 mg tablets NCT05978063 | Phase 2/3 | Pruritus |
| difelikefalin 0.25 mg NCT04018027 | Phase 2 | Pruritus |
| Difelikefalin NCT06593392 | Phase 2 | Pruritus |
| Difelikefalin Injection NCT05885763 | Phase 1 | End Stage Renal Disease on Hemodialysis |
Latest
No recent events.
Follow Difelikefalin on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.